German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek to widen the use of immunotherapy drug avelumab to include bladder cancer. The U.S. Food and Drug Administration will review trial data for the drug against locally advanced or metastatic urothelial carcinoma (mUC) which…

Britain’s decision to leave the European Union threatens to undermine its position as a center for drug research and UK patients could fall behind others in Europe in getting access to new drugs, Roche’s chief executive said. Currently, new drugs are approved by the European Medicines Agency, but in future Britain may have to set…